Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Six months' chemotherapy for lymph node tuberculosis.

O R McCarthy1, R M Rudd

  • 1Newham Chest Clinic, London, U.K.

Respiratory Medicine
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignant mesothelioma.

British medical bulletin·2010
Same author

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.

Thorax·2008
Same author

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

Lung cancer (Amsterdam, Netherlands)·2005
Same author

Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

Lung cancer (Amsterdam, Netherlands)·2004
Same journal

Adults with Congenital Lung Malformations: A Descriptive Analysis of an Underexplored Population.

Respiratory medicine·2026
Same journal

Risk Factors and Microbiological Characteristics of Ventilator-Associated Pneumonia in a Tunisian Intensive Care Unit During the COVID-19 Pandemic.

Respiratory medicine·2026
Same journal

Impact of Therapeutic Hypothermia on Oxygen Demand and Respiratory Function in Post-Cardiac Arrest Patients: A Retrospective Cohort Study.

Respiratory medicine·2026
Same journal

The longitudinal decrease in exercise tolerance and disease progression in mild-to-moderate COPD.

Respiratory medicine·2026
Same journal

The implications of adopting the race-neutral spirometry equations in the detection of airway obstruction in Chilean children with asthma.

Respiratory medicine·2026
Same journal

Long-term outcomes of home mechanical ventilation in Duchenne Muscular Dystrophy - an observational study.

Respiratory medicine·2026
See all related articles

Six-month chemotherapy for lymph node tuberculosis shows promising results, with most patients recovering fully. This short-course treatment may be as effective as longer regimens, warranting further study.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Oncology

Background:

  • Lymph node tuberculosis (TB) necessitates effective treatment strategies.
  • Short-course chemotherapy regimens are increasingly explored for various TB presentations.
  • Optimizing treatment duration balances efficacy with patient adherence and resource utilization.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of a six-month short-course chemotherapy policy for lymph node tuberculosis.
  • To compare the effectiveness of a 6-month regimen against historical 9-month standards.
  • To identify factors influencing treatment success and potential complications.

Main Methods:

  • Retrospective analysis of 41 patients with lymph node tuberculosis treated with a 6-month chemotherapy course.

Related Experiment Videos

  • Documentation of treatment completion, recovery rates, residual disease, and relapses.
  • Recording of treatment modifications due to side-effects, drug resistance, or other complications.

    • Main Results:

    • Forty-one patients completed the planned 6-month treatment.
    • Complete recovery was observed in most patients, with one showing residual disease and one relapse.
    • Nine patients required treatment changes, and seven had prolonged treatment durations for various reasons.

    Conclusions:

    • A 6-month chemotherapy regimen appears satisfactory for treating lymph node tuberculosis.
    • The findings support the potential non-inferiority of 6-month compared to 9-month regimens.
    • Further controlled comparative studies are needed to definitively establish the optimal treatment duration.